Commentary|Videos|October 21, 2025
Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore
Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Advertisement
Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, and Neal Shore, MD, FACS, of Carolina Urologic Research Center, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Advertisement
Related to this article
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.
Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
3
Dr Kuykendall on the Significance of the FDA Approval of Rusfertide for Polycythemia Vera
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5